PI3Kα (H1047R mutant) inhibitors reported in Reactive Biosciences patent
Oct. 10, 2024
Work at Reactive Biosciences Inc. has led to the discovery of new phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.